Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial

Keyphrases

• Clinical Trials 100%
• Sepsis 100%
• Patient Study 100%
• Elderly Patients 100%
• Fisetin 100%
• Senolytics 100%
• Slow Progression 100%
• Adaptive Resource Allocation 100%
• Immune Cells 40%
• Clinical Deterioration 40%
• Phase II Trial 20%
• Placebo 20%
• Phase I Study 20%
• Response to Infection 20%
• All-cause Mortality 20%
• Phase I Trial 20%
• Resistance Genes 20%
• Oral Dose 20%
• Double-blind Trial 20%
• Septic Shock 20%
• Single Oral Dose 20%
• Intensive Care Unit 20%
• Apoptosis Inhibition 20%
• Organ Failure 20%
• Failure-free 20%
• Trial Registration 20%
• Altered Gene Expression 20%
• Senescence-associated 20%
• Sepsis Diagnosis 20%
• Sepsis Shock 20%
• Clinical Diagnosis 20%
• CD3+ Cells 20%
• Senescent Cells 20%
• Quick Sequential Organ Failure Assessment (qSOFA) 20%
• Car-Free Day 20%
• Potential Contributor 20%

Immunology and Microbiology

• Prevalence 100%
• Immunocompetent Cell 100%
• Infectious Disease 50%
• Gene Expression 50%
• All Cause Mortality 50%
• Cardiovascular System 50%
• CD3 Antigen 50%
• Programmed Cell Death 50%
• Infection 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Fisetin 100%
• Sepsis 100%
• Prevalence 40%
• Deterioration 40%
• Placebo 20%
• Infection 20%
• All Cause Mortality 20%
• Organ Dysfunction Score 20%
• CD3 Antigen 20%
• Septic Shock 20%